Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy | ||||
| Archives of Pharmaceutical Sciences Ain Shams University | ||||
| Article 1, Volume 3, Issue 2 - Serial Number 6, June 2019, Page 130-141 PDF (1.26 MB) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/aps.2019.14995.1006 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hoda Sobhy Ibrahim  1; Deena S. Lasheen2; Rabah A. T. Serya3; Dalal Abd-ELRahman Abu-ELElla4
| ||||
| 1Pharmaceutical chemistry department, Faculty of pharmacy, Ain Shams University, Cairo, Egypt | ||||
| 2Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo11566, Egypt | ||||
| 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt | ||||
| 4Pharmaceutical chemistry department, Faculty of Pharmacy,Ain Shams University, Cairo, Egypt | ||||
| Abstract | ||||
| Apoptosis is a normal physiological process which is very crucial to maintain tissue homeostasis. Dysregulated apoptosis can lead to various diseases as cancer. Thus, evasion of apoptosis stands out as a key hallmark of cancer cells. Bcl-2 family of proteins is the key modulator of the mitochondrial apoptotic pathway. Therefore, the balance between the anti-apoptotic (BCL-2, BCL-XL and MCL-1) and pro-apoptotic (BAK, BAX, BAD, PUMA and NOXA) members of this family will govern cell fate. Overexpression of anti-apoptotic BCL-2 members including MCL-1 is implicated in the progression of many human cancers as well as the emerging resistance to various anti-cancer agents including targeted therapies. Indeed, inhibition of the anti-apoptotic BCL-2 members by small molecule BH3 mimetics may provide an excellent approach in cancer therapy. Unfortunately, it was reported that MCL-1 overexpression is linked to Venetoclax, first FDA approved BCL-2 selective inhibitor, resistance in AML. Thus, inhibition of MCL-1 with a selective small molecule inhibitor may provide an attractive strategy in cancer targeted therapy. Recently, several small molecule MCL-1 selective inhibitors have been developed and few are testing in clinical trials. Herein, we will discuss the recent advances in the development of selective small molecule MCL-1 inhibitors. | ||||
| Keywords | ||||
| apoptosis; Bcl-2; MCL-1; BH3 mimetics; Bax; Bak | ||||
|
Statistics Article View: 632 PDF Download: 647 |
||||
